Genmab Halts PTK7 ADC Development; Two Biotechs File for Hong Kong IPO
Genmab
Differentiated Antibody Therapy Developer
ArkBio
Innovative Drug Developer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Lion TCR
Developer of Novel Immunotherapies
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
An asset of Propharm Biotech has been abandoned by Genmab.
Recently, according to the Clinicaltrials website, Genmab terminated the Phase I clinical development of the PTK7 ADC drug PRO1107, primarily due to the overall risk-benefit ratio not supporting continued development.
The craze for Hong Kong IPOs continues.
On September 15, the website of the Hong Kong Stock Exchange showed that New Element Pharmaceuticals and ArkBio submitted their IPO applications to the Hong Kong Stock Exchange on the same day.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) Two Innovative Pharmaceutical Companies Apply for HKEX IPO
On September 15, the website of the Hong Kong Stock Exchange showed that New Element Pharmaceuticals and ArkBio submitted their IPO applications to the Hong Kong Stock Exchange on the same day.
/ 02 /
Pharmaceutical News
1) AstraZeneca's AZD9574 Receives Clinical Approval
On September 16, according to the CDE official website, AstraZeneca's AZD9574 received clinical approval and is proposed to initiate research for the treatment of advanced solid tumors.
2) Novo Nordisk's IcoSema Injection Receives Clinical Approval
On September 16, according to the CDE official website, Novo Nordisk's IcoSema injection received clinical approval and is intended for the treatment of type 2 diabetes (specific population: type 2 diabetes patients with inadequate blood glucose control after daily premixed insulin therapy).
3) Megeray Biologics' MR001 Bispecific Antibody Injection Receives Clinical Approval
On September 16, according to the CDE official website, Maijia Rui Biologics' MR001 bispecific antibody injection received clinical approval and is proposed to be used in combination with standard chemotherapy regimens for the treatment of locally advanced or metastatic pancreatic ductal adenocarcinoma.
4) Laien Bio's TCR-T Therapy for Hepatitis B Approved for IND in the United States
On September 15, LioCyx-M004, an innovative mRNA-encoded TCR-T cell therapy product developed by Guangzhou Laien Biological Medicine Co., Ltd., received approval from the U.S. FDA to initiate a Phase 1b/2 clinical trial (IND) for the treatment of chronic hepatitis B (CHB).
/ 03 /
Overseas Pharmaceutical News
1) Genmab Terminates PTK7 ADC Drug Development
Recently, according to the ClinicalTrials website, Genmab terminated the Phase I clinical development of the PTK7 ADC drug PRO1107, primarily due to an unfavorable overall risk-benefit ratio that could not justify continued development.
PS: Welcome to scan the QR code below to add the WeChat ID of AminoJun for communication.
